Method of implanting biostable elastomeric polymers having quaternary carbons

• US 6,102,939 A
• Filed: 10/15/1997
• Issued: 08/15/2000
• Est. Priority Date: 07/29/1996
• Status: Expired due to Term

• Current Assignee: Lifeshield Sciences LLC (Acacia Research Corporation)
• Original Assignee: Corvita Corporation (Boston Scientific Corporation)
• Inventors: Pinchuk, Leonard
• Primary Examiner(s): Prebilic, Paul B.
• Application Number:
  US08/951,016
• Time in Patent Office: 1,035 Days
• Field of Search: 623/1, 623/6, 623/11, 623/901, 607/1, 607/2, 607/9, 607/11, 600/36
• US Class Current: 623/23.58
• CPC Class Codes: A61L 27/16 obtained by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: B29C 41/08 Coating a former, core or other substrate by spraying or fluidisation, e.g. spraying powder spray-up of reinforcing fibres B29C70/305
• CPC Class Codes: B29L 2031/7532 Artificial members, protheses
• CPC Class Codes: C08L 53/00 Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
• CPC Class Codes: Y10S 623/901 Method of manufacturing prosthetic device

Abstract

An article of manufacture and method of making and implanting the article made of a polyolefin star or linear copolymer are disclosed in which the polyolefin copolymer is biostable and crack-resistant when implanted in vivo. The polyolefin copolymer is the reaction product of a rubbery component which when homopolymerized produces a polymer having a low level of hardness, and a hardening component which when homopolymerized produces a polymer having a high level of hardness. The polyolefin copolymer is elastomeric, has a hardness intermediate the low and high levels of hardness, and has a backbone in which the majority of polymer linkages along the copolymer chain are alternating quaternary and secondary carbon atoms.

Claims

1. A method of implanting a biostable prosthesis, comprising the steps of:

providing a crack-resistant biostable prosthesis by a process of extruding, molding, spraying, casting or forming a film of polyolefin copolymer on a surface to form said crack-resistant, biostable prosthesis;

said polyolefin copolymer comprising a first rubbery component which when homopolymerized produces a polymer having a low level of hardness, a second hardening component which when homopolymerized produces a polymer having high level of hardness to form a polyolefin copolymer which is elastomeric and has a hardness intermediate said low and high levels of hardness, and the polyolefin copolymer having a backbone in which the majority of polymer linkages along the copolymer chain are alternating quaternary and secondary carbon atoms; and

implanting said crack-resistant biostable prosthesis under in vivo implantation conditions whereby cracking of said polyolefin polymer is substantially prevented during in vivo implantation for substantial periods of time.

2. The method of claim 1, wherein said polyolefin copolymer is a star or linear copolymer.

3. The method of claim 1, wherein the polyolefin copolymer has the formulation:

##STR11## where R and R'"'"' are non-cyclic or cyclic aliphatic moieties having from 1 to about 8 carbon atoms, R" is a hydrogen, hydroxyl, methyl or ethyl group, and R'"'"'" is an aromatic phenyl group, aromatic benzyl group, aromatic substituted benzyl group, COOCH₃, methoxy, ethoxy, aliphatic, cycloaliphatic, or substituted aliphatic, and such that homopolymers of ##STR12## have a high level of hardness, n and m are from about 250 to about 5000, and p is about 1-10.

4. The method of claim 1, wherein the polyolefin copolymer has the formulation:

##STR13## where R and R'"'"' are non-cyclic or cyclic aliphatic moieties having from 1 to about 8 carbon atoms, R" is a hydrogen, hydroxyl, methyl or ethyl group, and R'"'"'" is an aromatic phenyl group, aromatic benzyl group, aromatic substituted benzyl group, COOCH₃, methoxy, ethoxy, aliphatic, cycloaliphatic, or substituted aliphatic, and such that homopolymers of ##STR14## have a high level of hardness, n and m are from about 250 to about 5000, and p is about 1-10.

5. The method of claim 1, wherein the copolymer has a hardness in the range of about Shore 20A to about Shore 75D.

6. The method of claim 5, wherein said hardness of the copolymer is in the range of about Shore 40A to about Shore 90A.

7. The method of claim 3, wherein the copolymer has a hardness in the range of about Shore 20A to about Shore 75D.

8. The method of claim 7, wherein said hardness of the copolymer is in the range of about Shore 40A to about Shore 90A.

9. The method of claim 4, wherein the copolymer has a hardness in the range of about Shore 20A to about Shore 75D.

10. The method of claim 9, wherein said hardness of the copolymer is in the range of about Shore 40A to about Shore 90A.

11. The method of claim 1, wherein said second hardening component is present in the amount of about 20 wt % to about 80 wt %.

12. The method of claim 11, wherein said amount is about 30 wt % to about 50 wt %.

13. The method of claim 3, wherein said second hardening component is present in the amount of about 20 wt % to about 80 wt %.

14. The method of claim 13, wherein said amount is about 30 wt % to about 50 wt %.

15. The method of claim 4, wherein said second hardening component is present in the amount of about 20 wt % to about 80 wt %.

16. The method of claim 15, wherein said amount is about 30 wt % to about 50 wt %.

17. The method of claim 3, wherein the combined molecular weight of said copolymer is between about 90,000 and about 300,000 Daltons.

18. The method of claim 1, wherein the crack-resistant biostable prosthesis is formed as an endoluminal or vascular device for in vivo implant.

19. The method of claim 2, wherein the crack-resistant biostable prosthesis is formed as an endoluminal or vascular device for in vivo implant.

20. The method of claim 3, wherein the crack-resistant biostable prosthesis is formed as an endoluminal or vascular device for in vivo implant.

21. The method of claim 4, wherein the crack-resistant biostable prosthesis is formed as an endoluminal or vascular device for in vivo implant.